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Abstract
Parkinson’s disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy 
neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD 
is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 
1–120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of 
α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated 
with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic 
nerve cell death starting from 6 and 12 months of age, respectively. In the MI2 mice, alterations in gait impairment can be 
detected by the DigiGait test from 9 months of age, while gross motor deficit was detected by rotarod test at 20 months of age 
when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an 
increase in the number and density of 20–500 nm α-synuclein species as shown by dSTORM. Treatment with the oligomer 
modulator anle138b, from 9 to 12 months of age, restored striatal dopamine release, prevented dopaminergic cell death and 
gait impairment. These effects were associated with a reduction of the inner density of large α-synuclein aggregates and an 
increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progres-
sive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor 
alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor 
deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b’s function 
in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD.
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Introduction
Parkinson’s disease (PD) and other α-synucleinopathies 
are characterized by aggregation of α-synuclein (αSyn) 
in Lewy bodies (LBs), Lewy neurites (LNs) and glial 
cytoplasmic inclusions [17, 32, 33]. It is now widely 
accepted that the process of αSyn aggregation in PD is 
directly involved in the pathogenesis and progression of 
the disease, and motor symptoms are mainly related to 
the dysfunction of the nigrostriatal dopamine (DA) sys-
tem. Indeed, an impairment of DA neurotransmission in 
the striatum and loss of DA neurons in substantia nigra 
pars compacta (SNpc) are observed at the time of PD 
diagnosis [16]. To date, there is no treatment that affects 
the mechanism of the disease, and existing therapies are 
symptomatic.
Availability of an animal model of PD that reproduces 
progressive DA dysfunction and DA neuronal death with 
progressive αSyn aggregation in the nigrostriatal system is 
crucial for understanding disease mechanisms and the test-
ing of novel therapies for treating movement deficit. In addi-
tion, until recently it was difficult to study quantitatively the 
early steps of αSyn aggregation and the effects of aggregate 
inhibitors in a living system, mainly due to the limitations in 
the diffraction of conventional microscopy. Today, with the 
use of super resolution microscopy like STORM, dSTORM, 
STED and aptamer DNA PAINT [30] and advanced analysis 
algorithms [3], it is possible to identify changes in αSyn 
aggregation at the single molecule level also in in vivo sys-
tems and understand the mechanistic nature of aggregate 
inhibitors.
Here, we report a new transgenic mouse model (MI2 
mice) expressing human 1–120 truncated αSyn that 
develops a progressive phenotype including αSyn aggre-
gation, loss of striatal DA, reduction in induced striatal 
DA release, DA neuron death in SNpc, loss of nigro-
striatal dopaminergic innervation, and motor deficits. 
We show that progressive DA dysfunction is associated 
with increased formation of synaptic striatal αSyn aggre-
gates. Moreover, we show that the oligomer modulator, 
anle138b, previously shown to be effective in other models 
of protein aggregation including αSyn [15, 23, 36, 37], 
restores striatal DA release and prevents DA cell loss and 
motor behavior even when administration is started after 
the onset of DA dysfunction. For the first time and using 
dSTORM and immunoblotting, we show that in vivo, in 
mouse brain, anle138b rescue of the DA deficit is associ-
ated with reduction of the density of dense αSyn aggre-




This study aimed to generate and characterize a novel trans-
genic mouse model of PD that would enhance our under-
standing of the relationship between progressive αSyn 
aggregation and mechanisms of disease and allow testing 
prospective therapies for α-synucleinopathies. The homozy-
gous line expressing 1–120 hαSyn under the TH promoter, 
in a null endogenous αSyn background was generated and 
used for the experiments. The αSyn-null C57Bl/6S strain 
was used as a control line. C57Bl/6J mice, expressing endog-
enous mouse αSyn were also included in the experiments 
where transgenic protein expression was compared to physi-
ological mouse αSyn. Moreover, DA characteristics in MI2 
mice were compared with both C57Bl/6S and C57Bl/6J 
mice to confirm that differences between C57Bl/6S and 
MI2 mouse lines were due to the expression of the transgene 
rather than the absence of αSyn in the C57Bl/6S animals.
MI2 and control mice were obtained from separate lines, 
therefore their genotypes were known at the time of experi-
mental design. However, for behavioral experiments and 
anle138b-treatment mice were assigned randomly to the 
experimental groups. For each experiment, mouse numbers 
and statistical tests are described in the figure legends and 
in Online Resource. Analysis of dopaminergic impairment, 
namely measurements of DA in striatal homogenates and 
microdialysates, stereological counting of nigral cells and 
striatal innervation were performed by researchers blinded 
to experimental conditions.
Generation of transgenic mice
The MI2 mouse line was generated using the same proce-
dures as described by Tofaris et al. for α-Syn120 mice [35]. 
Briefly, a transgene construct containing human truncated 
1–120 αSyn, subcloned downstream of the rat TH promoter 
(Fig.  1a) was injected into αSyn-null C57Bl/6OlaHsd 
(C57Bl/6S) mouse [31] pronuclei. The presence of the 
transgene was detected in the founders and progeny by PCR. 
Founders were then bred with αSyn-null C57Bl/6S mice and 
mouse αSyn-negative/1–120 hαSyn-positive progeny were 
crossed to homozygosity.
Western blotting
Animals were sacrificed by cervical dislocation, brains were 
snap frozen on dry ice and kept at − 80 °C. Brain regions 
were isolated, homogenized in ice-cold PBST [1 × PBS 
(Gibco), 0.3% Triton X-100 (Sigma), protease inhibitor 
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cocktail (Roche)] and centrifuged at 4 °C, at 14,000×g, for 
15 min. Supernatant protein content was measured using a 
BCA protein assay kit (Novagen) and protein concentration 
normalized using PBST.
To analyze the solubility of 1–120-hαSyn species, 
sequential extraction of protein was performed using buff-
ers of increasing strength. Following dissection, tissue was 
homogenized in TBS, incubated on ice for 15 min and cen-
trifuged at 120,000×g for 30 min, at 4 °C. The supernatant 
was collected for western blotting analysis, and the pellet 
was washed three times with TBS, resuspended in TBS + 1% 
Triton-X100, incubated on ice for 15 min and centrifuged 
at 120,000×g for 30 min at 4 °C. These steps were then 
repeated using RIPA buffer (50 mM Tris, pH 8.0, 150 mM 
NaCl, 0.1% SDS, 0.05% sodium deoxycholate, 1% NP-40), 
and 8 M urea (Sigma) with 5% SDS (Sigma), with the excep-
tion that urea/SDS step was performed at room temperature 
rather than 4 °C. All the solutions used in this procedure 
were supplemented with 1 × protease inhibitor cocktail.
Following 5 min at 95 °C in 1 × Laemmli buffer, samples 
were separated by SDS-PAGE, blotted onto nitrocellulose 
membranes (Bio-Rad) and proteins were crosslinked to the 
membrane with 4% paraformaldehyde (PFA) for 30 min. 
Non-specific background was blocked with 5% milk in 
TBST before overnight incubation of the membrane at 4 °C 
with primary antibodies (mouse anti-αSyn (Syn1), BD 
Biosciences, 1:500; rabbit anti-TH, Abcam, 1:1000; rab-
bit anti-β-actin, Abcam, 1:10,000) in 5% milk. Membranes 
were then incubated with peroxidase-conjugated secondary 
antibodies (GE Healthcare or DAKO, 1:5000) and the blots 
imaged using a Chemi Doc MP imager (Bio-Rad), using 
West Dura Extended Duration Chemiluminescent Substrate 
(Thermo Fisher Scientific). Blots were analyzed using Image 
Lab 5.1 (Bio-Rad Laboratories).
Bands corresponding to mouse full length monomeric 
(~ 17 kDa) and 1–120 truncated human αSyn (~ 14 kDa) 
were observed in C57Bl/6J and MI2 mice, respectively. No 
αSyn was present in C57Bl/6S (Fig. 1c). Non-specific bands 
recognized by the Syn1 antibody were previously reported 
(Fig. 2c) [29].
Immunohistochemistry
Mice were anesthetized by an intraperitoneal administra-
tion of pentobarbital (Merial Animal Health) and transcar-
dially perfused with ice-cold PBS, followed by 4% PFA 
in PBS. Brains were post-fixed overnight in 4% PFA, then 
transferred to 30% sucrose in PBS with 0.1%  NaN3 (Sigma) 
and stored at 4 °C. Brains were frozen and 30 µm sections 
cut using a freezing microtome (Bright). Endogenous per-
oxidase activity was inhibited by treatment with 3%  H2O2 
containing 20% methanol in PBST. Sections non-specific 
background was blocked with 5% normal horse serum (NHS, 
Vector) in PBST. Antigen retrieval was performed before 
Syn1 staining, using 10 mM sodium citrate buffer pH 8.5 
at 80 °C for 30 min. Free floating sections were incubated 
overnight at RT with primary antibodies diluted in PBST 
(Syn1, 1:500; rabbit or chicken anti-TH, Abcam, 1:1000; 
mouse anti-NeuN, Millipore, 1:1000, rabbit anti-VAMP2, 
Abcam, 1:250; rabbit anti-ubiquitin (Ubi-1), Millipore, 
1:500) and then with biotinylated (Vector, 1:2000) or Alexa 
Fluor-conjugated (Thermo Fisher Scientific, 1:500) sec-
ondary antibodies diluted in PBST containing 5% NHS. 
Peroxidase-based staining was developed using Vectastain 
Elite ABC HRP Kit (Vector) and DAB Peroxidase Sub-
strate Kit (Vector). Sections were mounted on microscope 
slides, dehydrated, cleared in xylene and coverslipped using 
DPX Mountant (Sigma). In some experiments, sections 
were counterstained with 0.1% cresyl violet (Sigma). For 
immunofluorescence nuclei were counterstained with DAPI 
(0.5 µg/ml; Roche) and sections coverslipped using Fluor-
Save mounting medium (Calbiochem).
To determine the presence of filamentous αSyn aggre-
gates, brain sections from MI2 and control mice were 
incubated with either Thioflavin T (TfT, Sigma; 0.2 μM 
in deionized water, for 10 min) or pentameric formyl thio-
phene acetic acid (pFTAA, kind gift from P. Nilsson; 0.5 μM 
in PBST, for 45 min). αSyn staining with Syn1 antibody, 
revealed by 647 nm Alexa Fluor-conjugated secondary anti-
body, was performed before TfT or pFTAA to determine 
the specificity of the staining. Sections were washed exten-
sively with PBST before incubation with DAPI. To further 
investigate the solubility of the αSyn aggregates serial sec-
tions were treated with proteinase PK (PK; Sigma) prior to 
αSyn immunohistochemistry to digest soluble αSYN. Prior 
to the non-specific background blocking step, the slices were 
incubated with PK (20 μg/ml, 10 min, 37 °C, at RT), and 
washed twice with PBST supplemented with 5 mM phenyl-
methylsulfonyl fluoride (PMSF; Sigma) to inhibit residual 
PK activity. For these experiments immunostaining to detect 
αSyn was performed with Syn1 antibody as described above. 
DAB-stained sections were analyzed using Olympus BX 53 
light microscope and fluorescent sections using a Leica DMI 
4000B epifluorescent microscope.
For dSTORM, 30 µm free floating striatal slices were 
stained using a similar protocol, but PBST containing 0.25% 
Tween 20 was used and the non-specific background block-
ing solution contained 5% goat serum and 1% bovine serum 
albumin. Sections were stained with Syn204 mouse anti-
human αSyn antibody (Abcam, 1:250) and Alexa Fluor 647 
secondary anti-mouse antibody (Thermo Fisher Scientific, 
1:500). In some experiments striatal sections were co-
stained with rabbit anti-synaptobrevin 2 (VAMP2) antibody 
(Synaptic Systems, 1:500), followed by Cy3B anti-rabbit 
secondary antibody (1:250) to confirm synaptic localization 
of 1–120 hαSyn by dSTORM.
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dSTORM
dSTORM images were taken using the Vutara microscope 
as described in [3], at power of 40% 647 and 2% 405 laser, 
and 3000 frames were taken for each movie. Localizations 
were gathered following the movie with a ratio of 10 of 
background to noise. All movies were then post analyzed 
using a denoise level of 0.5.
Cluster analysis, mean diameter cluster analysis and the 
number of localizations per clusters were determined using 
the density based algorithm (dbscan) followed by 2D princi-
pal component analysis and outliers detection as described in 
[3] (see Supplementary Fig. S4, Online Resource 1 for more 
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details). For anle138b vs placebo treatment analysis, clusters 
in both conditions were additionally filtered according to 
inner density threshold determined according to the placebo 
condition per imaging day to avoid large-homogenous dis-
tributions that could form artifact clustering. Mean density 
of cluster was calculated for the placebo condition on the 
individual day of measurement and clusters with less than 
10% of this density were excluded from analysis in both 
placebo and anle138b treatment conditions measured on the 
same day. The localizations that were accounted for very 
low-density clusters were in both cases added to the free 
(unclustered) populations of the proteins.
Additional information on analysis of dSTORM data are 
given in Online Resource.
Dopamine and DOPAC measurements
Bilateral striata were isolated from frozen brains, weighed 
and homogenized in 0.2 M perchloric acid. Homogenates 
were centrifuged at 6000×g for 20 min at 4 °C. The super-
natants were resolved by high-performance liquid chroma-
tography with a Hypersil BDS C18 reversed phase column 
(3 µm particle size, 130 Å pore size, 100 × 4.6 mm; Phe-
nomenex) at a flow rate of 1 ml/min as previously reported 
[12]. The mobile phase comprised of citric acid (31.9 g/l), 
sodium acetate (2 g/l), octanesulfonic acid (460 mg/l), 
EDTA (30 mg/l) and methanol (15%), pH 3.6. DA, and 
its metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) 
were detected by redox oxidation using an ESA 5014 ana-
lytical cell and ESA Coulochem II electrochemical detector 
(Thermo Fisher Scientific) with reducing (E1) and oxidizing 
(E2) electrodes set at − 200 mV and + 250 mV, respectively. 
The chromatograms were analyzed using the Chromeleon 
Chromatography Data System (V 6.2; Dionex). DA and 
DOPAC levels were normalized to the initial wet tissue 
weight and expressed as pmol/mg.
In vivo microdialysis
Animals were anesthetized with Caprieve and isoflurane and 
placed in a stereotaxic frame under general anaesthesia. A 
craniotomy was drilled in the skull according to the following 
coordinates relative to bregma: + 0.8 anteroposterior, + 2.1 
lateral [28]. The guide cannula CMA7 (CMA Microdialysis) 
was implanted in the brain, so that its tip reached the calloso-
striatal border, − 2.3 mm dorsoventral relative to the skull 
surface [28], and was secured to the skull using glass ionomer 
luting cement FujiCEM 2 (GC Corporation) and two anchor 
screws CMA7431021 (CMA Microdialysis). Microdialysis 
was performed 24 h following the surgery when the mice had 
recovered. A microdialysis probe CMA7 (0.24 mm × 2 mm 
membrane, 6 kDa cut-off; CMA Microdialysis) was inserted 
through the guide cannula, and freely-moving mice were 
infused with artificial cerebro-spinal fluid (ACSF; 140 mM 
NaCl, 7.2 mM glucose, 3 mM KCl, 1 mM  MgCl2, 1.2 mM 
 CaCl2, 1.2 mM  Na2HPO4, 0.27 mM  Na2HPO4, pH 7.4) at 
2 µl/min. An equilibration period of 30 min was allowed to 
recover basal levels of extracellular DA in striatum, and then 
dialysates were collected every 20 min in ice-cold tubes con-
taining 5 µl of 0.2 M perchloric acid. After 60 min, ACSF 
was replaced with high-potassium ACSF (93 mM NaCl and 
50 mM KCl), to induce neurotransmitter release, and a fur-
ther 3 samples were collected, after which the physiological 
ACSF was infused again. Each sample was snap frozen in dry 
ice and stored at − 80 °C until HPLC analysis was performed 
as described above. Mice were sacrificed and the microdi-
alysis probe position was verified in the striatum. For each 
individual mouse, DA release was normalized to the baseline 
fraction (0 min) and expressed as fold difference relative to 
the average DA release directly following  K+ stimulation 
(60 min fraction) in the respective control C57Bl/6S group. 
DA release was compared between MI2 and C57Bl/6S mice 
and between anle138b- and placebo-treated mice.
Stereological counting of nigral cells
Six 30 µm-thick coronal sections, evenly spaced at 180 µm 
within the range covering the whole SNpc (between 
− 2.8 mm and − 3.85 mm AP from bregma [28]), were 
investigated in each mouse. TH immunohistochemistry 
was performed as described above, and tissue sections were 
analyzed with the optical fractionator probe using Stereo 
Investigator 11.07 (MBF Bioscience) with Olympus BX53 
microscope equipped with QImaging Retiga camera and 
X-Y step motorized stage controlled by MAC 6000 System 
Fig. 1  Expression of transgenic 1–120  hαSyn in MI2 mice. a 
1–120 hαSyn transgene construct used for generating the MI2 mice. b 
Immunoblots showing αSyn in lysates from cerebellum (Cbl), cortex 
(Ctx), substantia nigra (SN), striatum (Str) and olfactory bulbs (OB) 
of 1.5  month-old mice following short (short exp) and long (long 
exp) exposure times. Quantification was performed for SN, Str and 
OB, but not for Cbl and Ctx, where the signal was negligible. Data 
are expressed as fold difference compared to SN (mean ± SEM, n = 3 
mice, one-way ANOVA with Bonferroni correction (**p < 0.01, 
***p < 0.001) (detailed statistics in Online Resource). c Immunob-
lots comparing expression levels between control and MI2 mouse 
lines. Expression of 1–120 hαSyn (αS(1-120)) in MI2 mice is much 
lower than that of endogenous full-length αSyn (fl) in WT C57Bl/6J 
in the OB. Interestingly some truncated αSyn with a similar size to 
the transgenic 1–120 hαSyn can be seen in protein extracts of SN and 
Str of WT C57Bl/6J mice. d Immunohistochemistry of brain sections 
of 1.5 month-old MI2 mice detected with the Syn1 antibody shows 
1–120 hαSyn protein in neuronal cell bodies and processes in SNpc 
and ventral tegmental area (VTA) and in neuropil in striatum (see 
also Supplementary Fig. S1a, Online Resource 1). In C57Bl/6J mice, 
endogenous αSyn, is also found in SN pars reticulata (SNpr) and Ctx 
besides SNpc, VTA and Str. The specificity of Syn1 antibody for 
αSyn was confirmed by the absence of staining in C57Bl/6S mice that 
lack endogenous αSyn
◂
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controller. The SNpc area was outlined under a 4x objective 
and cells were counted under a 100 × objective using the 
following parameters: counting grid size—220 × 220 µm, 
counting frame—85 × 85 µm. The thickness of the section 
was measured at each counting site. Data were processed 
using built-in software and the optical fractionator formula 
to estimate the total number of TH-positive neurons in SNpc.
In order to confirm neurodegeneration in SNpc of MI2 
mice, stereological counting of all nigral neurons was 
performed after staining the sections with the NeuN pan-
neuronal marker. In order to contour SNpc for NeuN cell 
counting, TH immunofluorescence was performed in the 
same sections and staining visualized with Alexa Fluor 488 
secondary antibody. Sections were visualised at 488 nm 
using an epifluorescent microscope and the SNpc was out-
lined based on TH immunofluorescence. The resulting con-
tour was super-imposed in the bright field image of NeuN 
immunohistochemistry. The slides were transferred to a ste-
reology microscope, and the contour of SNpc was manually 
reconstructed in bright field in Stereo Investigator 11.07 
before stereological counting of NeuN-positive cells (see 
also Supplementary Fig. S6, Online Resource 1).
Measurements of  TH+ striatal innervation
Density of dopaminergic fibers in the striatum was estimated 
by the modified spherical probe counting method [26] in 
two 30 µm-thick coronal sections, representing medial and 
caudal striatum (+ 0.12 mm and − 0.66 mm AP from bregma 
[28]). The tissue was processed for TH immunohistochemis-
try as described above and analyzed using Stereo Investiga-
tor 11.07. A series of hemispherical (10 µm radius) probes, 
arranged in a 2 dimensional array, spaced at 250 µm inter-
vals was superimposed on the striatum, and the total number 
of TH-positive fibers that cross the surface of the probe was 
counted under a 100 × objective. The thickness of the sec-
tion was measured at each counting site. The estimated total 
length of TH-positive fibres in individual sections was nor-
malized to the measured volume of the section and averaged 
between counting sites. Data are expressed as nm of length 
of TH-positive fibers in µm3 of striatal volume.
Rotarod test
Motor performance was tested using an accelerating rotarod 
(Ugo Basile). The test was performed in mice at 6, 12, 15 
and 20 months of age using separate cohorts of animals at 
each time point. Both males and females were tested in MI2 
and C57Bl/6S groups, but we observed that some 15 and 
20 month-old MI2 females were overweight, therefore, since 
the body weight may affect motor performance [20, 24], the 
heaviest individuals from this group were excluded from the 
test, to obtain no significant difference between the MI2 and 
C57Bl/6S females mice tested (t test, p = 0.552 at 15 months, 
p = 0.851 at 20 months). Prior to the test, mice were trained for 
2 days. Each training session consisted of four trials at constant 
speed of 16 rpm, for a maximum of 60 s per trial. Mice were 
then tested using the acceleration mode (5–40 rpm) for three 
consecutive days with three trials per day and with at least 
30 min intervals between the trials. Mice were placed on the 
rod and the time that the individual mouse took to fall from the 
rod was measured. Single trials were considered as technical 
replicates, and an average of 9 technical replicates (3 days per 3 
trials) was calculated for each animal to obtain each biological 
replicate that was then used for statistical purposes.
Static rod test
The cohort of 20 month-old mice used for the rotarod test 
were then used for the static rod test performed according to 
the method of Deacon with modifications [9]. Two 60 cm-
long rods of 25 mm and 15 mm diameters were attached to 
Fig. 2  Aggregation of 1–120  hαSyn protein in MI2 mice. a Top 
panel: progressive accumulation of 1–120  hαSyn protein with age 
in SNpc of MI2 mice in cell bodies (arrows) and processes (arrow-
heads). Middle panel: abundant small inclusions of 1–120 hαSyn pro-
tein in SNpc cell bodies are present at 1.5 months and large, LB-like 
aggregates in SNpc neurons (arrows) among cells with 1–120 hαSyn 
punctate staining (arrowhead) are found at 12  months of age. Bot-
tom panel: large 1–120 hαSyn puncta are distributed along the pro-
cesses in SNpc at 1.5 and 12 months of age (arrows). At 12 months 
of age, processes uniformly filled with 1–120  hαSyn (triangle) and 
round inclusions containing condensed 1–120 hαSyn protein (arrow-
heads) are also visible. The staining of αSyn in WT C57Bl/6J mice 
is much less intense and more homogenous. Middle right panel: less 
αSyn is present in cell bodies, and no cellular inclusions are found 
(arrow) in control mice. Bottom right panel: αSyn puncta in the 
nigral processes are much less numerous and smaller in C57Bl/6J 
mice than in MI2 mice (arrowheads), (see also Supplementary Fig. 
S2, Online Resource 1). b Progressive accumulation of 1–120 hαSyn 
puncta in MI2 striatal neuropil in 1.5, 6 and 12 month-old MI2 mice. 
In 12  month-old C57Bl/6J mice striatal αSyn is distributed more 
homogenously and large αSyn-positive puncta are not present (bot-
tom panel). c Immunoblotting of brain lysates from MI2 mice as a 
function of age. The levels of monomeric 1–120  hαSyn (~ 14  kDa, 
arrow) shown in the western blots were quantified and normalized to 
either β-actin or TH (right panels). Data are expressed as fold differ-
ence compared to 1.5  month-old animals (mean ± SEM, n = 3 mice, 
one-way ANOVA, multiple comparison with Bonferroni correc-
tions). In SN, a reduction of monomeric 1–120 hαSyn was found as 
a main effect of age [statistically significant differences between 1.5 
and 12 months and between 6 and 12 months (αSyn/β-actin or αSyn/
TH; *p < 0.05)] for all comparisons. In the striatum there was a sig-
nificant increase of 1–120  hαSyn between 1.5 and 6  months of age 
(*p < 0.05) for both αSyn/β-actin and αSyn/TH. There was no signifi-
cant change in OB. In all the three brain regions increased amounts of 
high molecular weight (HMW) 1–120 hαSyn bands (~ 55 kDa, arrow-
head) were present in MI2 mice at 12 months compared to 1.5 and 
6 months of age (see also Supplementary Fig. S3, Online Resource 
1). Stars denote the non-specific bands recognized by Syn1 antibody 
in both MI2 and αSyn-null C57Bl/6S mice [29] (see detailed statisti-
cal evaluation in Online Resource)
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the platform and held horizontally 30 cm above the cush-
ioned surface. Mice were placed at the end of the rod, fac-
ing away the platform and were allowed to freely turn back 
and walk to the platform. Prior to the test animals received 
training trials using 25 mm and 15 mm rods. On the next 
day, mice were tested on both 25 mm and 15 mm rods (one 
trial per each diameter). Two parameters were measured: 
orientation time (time taken to turn from the initial position 
towards the platform) and transit time (time taken to traverse 
the rod from the far end to the platform).
Gait assessment with the DigiGait system
In order to detect the presence of early motor behavior 
during the progression of αSyn aggregation and synaptic 
dysfunction in MI2 mice, we used DigiGait automated 
gait imaging system (Mouse Specifics Inc.) [14, 27]. MI2 
and control C57Bl/6S mice were tested at 3, 6, 9, 12, 15 
and 18 months of age. Male mice were selected because 
at older age some female MI2 mice appeared overweight 
and this could have influenced the results. Individual ani-
mals were weighed before the analysis, and placed on the 
transparent motorised treadmill, that was set at 10 cm/s, the 
speed was adapted to the performance of aged animals (up 
to 18 months) that were still able to walk steadily at this rate 
but not at higher speed. The camera placed under the belt 
captured the gait of each mouse individually at 150 frames/s, 
and 3–5 s-long video of steady walking was then selected for 
further analysis for each mouse. The videos were analyzed 
by the DigiGait software, that measured the area of paw-belt 
contact in subsequent frames of the video, and plotted it 
against time, producing a plot representing stepping cycles 
for each individual paw. The data were then automatically 
processed by the DigiGait software to calculate indices for 
individual paws. These results were analyzed after averaging 
fore right with fore left paw values and hind right with hind 
left paw for individual mice.
After the detection of a motor phenotype at early ages 
the test was repeated to determine whether anle138b had 
an effect on the motor behavior detected. However, because 
the number of male mice available at the correct age was not 
sufficient for statistically significant conclusions we com-
bined males and females taking care to select mice of simi-
lar weight. MI2 and C57Bl/6S animals treated with either 
anle138b or placebo diet were tested at 9 months of age 
(1 day prior to the treatment start), at 10.5 months of age (in 
the middle of the treatment period), and at 12 months of age 
(1 day prior to the treatment end).
Anle138b treatment
Mice were treated from 9 to 12 months of age with anle138b, 
starting at a time when loss of striatal DA release was 
already present in MI2 mice but prior to significant nigral 
neuron loss and completed when MI2 mice presented with 
no more than 30% cell loss. Drug or placebo was adminis-
tered in standard diet (2 g/kg of food, ssniff Spezialdiäten 
GMbH) throughout the whole 3 months study period to dif-
ferent cohorts of MI2 and C57Bl/6S mice. The levels of 
anle138b in plasma and brains of mice following this type of 
treatment have been previously reported [36]. At 12 months 
of age, mice were assessed using in vivo microdialysis. Sub-
sequently, brains were collected for analysis, as described 
above.
Statistical analysis
The results are expressed as mean ± SEM. A t test was used 
for comparisons between two experimental groups. When 
more than two means were compared, one-way or two-way 
ANOVA, followed by a Bonferroni correction for multiple 
comparisons was used. Data from the in vivo microdialysis 
experiments were analyzed using two-way or three-way mixed 
ANOVA, with sampling time point as within-subject factor.
Results
Generation of 1–120 hαSyn MI2 mouse line
MI2 mice express truncated 1–120 hαSyn under the control 
of the rat TH promoter (Fig. 1a), but no endogenous mouse 
αSyn due to a spontaneous deletion of the SNCA gene in the 
C57Bl/6OlaHsd (C57Bl/6S) mice [31, 35]. A C-terminally 
truncated form of αSyn was used because it has been shown 
to aggregate faster than the full-length protein [7] and its 
presence has been shown in brain extracts from Parkinson’s 
and dementia with Lewy bodies patients [1]. Immunoblot-
ting revealed the presence of the transgenic protein in brain 
regions and neurons with TH-expression, such as substan-
tia nigra (SN), striatum and olfactory bulb (OB), while no 
transgenic protein was expressed in cortex or cerebellum, 
where TH expression is not prominent (Fig. 1b). Expres-
sion of transgenic 1–120 hαSyn appeared significantly lower 
than that of endogenous αSyn in wild-type (wt) C57Bl/6J 
mice (Fig. 1c) possibly because αSyn is present in various 
neuronal populations in wt mice, while its expression in MI2 
mice is limited to  TH+ neurons.
By immunohistochemistry, the distr ibution of 
1–120 hαSyn also followed the TH expression pattern, 
staining being evident in SNpc and ventral tegmental area 
(VTA) neurons, while no staining was evident in the SN 
pars reticulata, where αSyn is instead found in wt C57Bl/6J 
mice (Fig. 1d). In the SNpc 1–120 hαSyn expression was 
localized in both neuronal cell bodies and processes, while 
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in the striatum, where nigral neurons project, it appeared as 
diffuse punctate staining (Fig. 1d).
Progressive aggregation of transgenic 1–120 hαSyn
Immunohistochemical analysis of 1–120  hαSyn in the 
nigrostriatal system of MI2 mice showed an age-dependent 
progressive accumulation of the protein. At 1.5 months, anti-
αSyn antibodies stained small puncta that were diffusely dis-
tributed throughout the cell body of nigral neurons as well 
as numerous swollen processes. A more intense pattern was 
observed at 6 months, and at 12 months of age when, besides 
the punctate αSyn immunoreactivity, large LB-like struc-
tures with condensed αSyn staining were seen, and neuronal 
processes were uniformly stained, with some containing 
large 1–120 hαSyn inclusions (Fig. 2a). None of these fea-
tures were present in wt C57Bl/6J mice, where at 12 months 
of age, normal αSyn puncta were much smaller and less 
frequent than the inclusions in the MI2 mice (Fig. 2a).
In the striatum the distribution of 1–120 hαSyn was con-
sistent with its synaptic enrichment, confirmed by co-stain-
ing with synaptobrevin (VAMP2), (Supplementary Fig. S1a, 
Online Resource 1) and followed the pattern of nigrostriatal 
projections. Staining for transgenic human 1–120 hαSyn 
appeared as small puncta, accompanied by larger inclusions, 
whose number increased with age (Fig. 2b), while wild type 
C57Bl/6J mice displayed a normal diffuse and homogene-
ous αSyn punctate pattern (Fig. 2b). No αSyn staining was 
present in wt C57Bl/6S mice with deletion of the endoge-
nous αSyn gene. Staining for VAMP2 showed a progressive 
redistribution of the protein at the synapse (Supplementary 
Fig. S1b, Online Resource 1), a pattern similar to that previ-
ously reported in our α-Syn120 mice showing SNARE protein 
redistribution [12].
Staining with anti-ubiquitin antibody was present in some 
large αSyn aggregates in the neurons of the SNpc starting 
from 12 months of age in MI2 mice (Supplementary Fig. 
S2b, Online Resource 1), but was not detected at any age in 
αSyn presynaptic aggregates in the striatum (data not shown). 
TfT and pFTAA did not show any specific staining (data not 
shown). PK digestion of tissue sections from SNpc and stria-
tum of MI2 mice at 1.5 and 12 months of age showed that, 
while in the SNpc some of αSyn aggregates were resistant 
to PK treatment and still detectable following treatment, no 
αSyn staining was found in the striatum indicating that aggre-
gates had been fully digested in this region or if present they 
were too small to be detected with conventional microscopy 
(Supplementary Fig. S2a, Online Resource 1).
Immunoblotting of SN extracts showed a significant 
reduction of monomeric 1–120 hαSyn in 12 month-old 
MI2 compared with 6 and 1.5 month-old MI2 mice with 
an associated increase in higher molecular weight (HMW) 
1–120 hαSyn species (Fig. 2c). In the striatum, monomeric 
1–120 hαSyn increased between 1.5 and 6 months of age 
and an increase in HMW species was present at 12 months 
of age, similar to the SN (Fig. 2c).
Serial extraction of αSyn with buffers of increasing 
strength from both SNpc and striatum showed an increase in 
the presence of αSyn in TritonX-insoluble fractions between 
1.5 and 12 months of age, suggesting increasing aggregates 
insolubility (Supplementary Fig. S3, Online Resource 1).
No apparent difference in monomeric 1–120 hαSyn was 
found in the OB between 1.5-, 6- and 12 months of age, 
although an increase in HMW bands was also present in this 
region (Fig. 2c).
Super‑resolution imaging of striatal 1–120 hαSyn
To obtain a more detailed analysis of synaptic 1–120 hαSyn at 
a near single-molecule resolution, we imaged the transgenic 
protein in the striatum of mice at 1.5, 6 and 12 months of age 
using dSTORM following immunofluorescence staining with 
a human αSyn specific antibody (Fig. 3a). To perform quan-
titative analysis of the aggregation profile, size, shape, inner 
density, local density per region of interest and percentage of 
aggregated 1–120 hαSyn, a semi-automated software was built 
that implements a novel set of meta-analysis clustering algorith-
mic tools for analyzing super-resolution data (Supplementary 
Fig. S4, Online Resource 1). Using this approach, we observed 
progressive aggregation of 1–120 hαSyn and followed the size 
distribution of the aggregates over time in the striatum of 1.5, 6 
and 12 month-old MI2 mice. No specific staining was observed 
by dSTORM in C57Bl/6S control mice (see also Supplemen-
tary Fig. S3, Online Resource 1) The population of aggregates 
was divided into 4 groups according to size: small, with a 
diameter ranging from 20 to 100 nm, medium, with a diameter 
between 100 and 300 nm, large, with a diameter of 300–500 nm 
and very large, with a diameter above 500 nm. dSTORM imag-
ing and analysis demonstrated an age-dependent increase in 
the overall number of 1–120 hαSyn aggregates from 1.5 to 6 
and 12 months of age (Fig. 3b). This increase was mainly due 
to an age-dependent increase in small (20–100 nm), medium 
(100–300 nm) and large (300–500 nm) aggregates. The number 
of very large aggregates (> 500 nm) did not significantly change 
with age (Fig. 3c).
Dopaminergic dysfunction in the striatum of MI2 
mice
To establish whether the progressive aggregation of 
1–120 hαSyn affected DA neurotransmission in the stria-
tum in MI2 mice, the total content of striatal DA was 
measured at 3, 6 and 12 months of age. No difference was 
detected between MI2 and C57Bl/6S control mice at 3 and 
6 months of age, while a significant reduction in total DA 
levels was present at 12 months (control, 65.3 ± 5.8, MI2, 
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38.1 ± 5.7 pmol DA/mg of tissue, Fig. 4a). DA content in 
12 month-old MI2 mice was also reduced compared to MI2 
mice at 3 and 6 months of age (87 ± 9.2 and 73.1 ± 11.1 pmol 
DA/mg of tissue, respectively; Fig. 4a). No difference was 
found in DA levels at 12 months of age between control 
mouse lines with (C57Bl/6J) and without (C57Bl/6S) endog-
enous αSyn (Supplementary Fig. S5a, Online Resource 1), 
confirming that the absence of endogenous αSyn does not 
affect striatal DA levels, as previously shown [13].
Dopaminergic deficit in MI2 mice was further investi-
gated by measuring striatal DA release using in vivo micro-
dialysis. DA release was induced in freely moving mice 
by infusion of 50 mM  K+. No difference in DA release 
was observed between MI2 and control C57Bl/6S mice at 
3 months of age, while at 6 months, a significant reduc-
tion in  K+ stimulated DA release was present in MI2 mice 
compared with C57Bl/6S controls [samples were measured 
at 60, 80 and 100 min, normalized to peak C57Bl/6S value 
(at 60 min)] (0.57 ± 0.15 vs 1 ± 0.08 at 60 min, 0.38 ± 0.09 
vs 0.63 ± 0.07 at 80 min, and 0.34 ± 0.03 vs 0.54 ± 0.05 
at 100 min in MI2 vs control mice; Fig. 4b). This impair-
ment was progressive, with the loss of induced DA release 
being more prominent at 9 months of age (0.24 ± 0.09 vs 
1 ± 0.25 at 60 min, 0.17 ± 0.06 vs 0.71 ± 0.17 at 80 min, and 
0.17 ± 0.06 vs 0.6 ± 0.14 at 100 min in MI2 vs control mice) 
and further exacerbated at 12 months of age (0.16 ± 0.06 vs 
1 ± 0.24 at 60 min, 0.13 ± 0.05 vs 0.87 ± 0.2 at 80 min and 
0.11 ± 0.04 vs 0.61 ± 0.17 at 100 min in MI2 vs control mice; 
Fig. 4b). No difference was observed in striatal DA release 
between C57Bl/6S and C57Bl/6J control mice at 12 months 
of age (Supplementary Fig. S5b, Online Resource 1). These 
findings indicate that striatal DA release impairment in 
Fig. 3  dSTORM analysis of the progression of 1–120 hαSyn aggre-
gation in the striatum of MI2 mice. a Representative dSTORM 
images of 1–120 hαSyn staining in the striatum of MI2 mice at 1.5, 
6 and 12  months of age showing increasing number of aggregates 
with age. b Quantification of dSTORM data (see also Supplemen-
tary Fig. S4) (mean ± SEM, n = 3 mice, one-way ANOVA, multiple 
comparisons with Bonferroni correction). The main effect of age is 
the increasing number of aggregates (clusters) (*p < 0.05). No dif-
ferences in the aggregate median size or number of localizations per 
cluster (e.g. the inner density which measures the number of fluo-
rescent flashes in a cluster) were found. c Analysis of cluster size 
distribution shows a statistically significant increase in the number 
of small-size aggregates (20–100  nm, t test #p < 0.05), medium size 
aggregates (100–300 nm, one way ANOVA, *p < 0.05) and large-size 
aggregates (300–500 nm, one way ANOVA, *p < 0.05), between 1.5 
and 12  months of age (see detailed statistical evaluation in Online 
Resource)
585Acta Neuropathologica (2019) 138:575–595 
1 3
MI2 mice is associated with the progressive aggregation of 
1–120 hαSyn. Importantly, a significant reduction in DA 
release in MI2 mice appears earlier than a reduction of total 
DA content in striatal tissue extracts, supporting the pres-
ence of a specific synaptic dysfunction (Fig. 4).
Loss of dopaminergic neurons in SNpc of MI2 mice
Nigral DA neuron death in the MI2 mice was investigated 
by unbiased stereological counting of cells stained for TH. 
The results showed a progressive  TH+ cell loss in SNpc of 
MI2 mice compared to C57Bl/6S mice starting at 9 months 
of age (MI2, 11,174 ± 825.1 vs control, 13,222 ± 1658.8 
 TH+ neurons) becoming significant at 12 months of age 
[31% reduction in MI2 vs control mice: 8530.4 ± 751.9 
(MI2) vs 12,398.8 ± 946.1 (C57Bl/6S)] and further pro-
gressed at 20 months of age [54% reduction in MI2 vs con-
trols: 6345.3 ± 523.1 (MI2) vs 13,836 ± 616.1 (C57Bl/6S) 
 TH+ neurons, respectively] (Fig. 5a, b). The number of 
 TH+ cells in SNpc of 20 month-old MI2 mice was also 
Fig. 4  Striatal dopaminergic deficit in MI2 mice. a DA was measured 
in striatal lysates of MI2 and C57Bl/6S mice at 3, 6 and 12 months 
of age (mean ± SEM, n = 5–8 mice per group). A main effect of age 
and interaction between genotype and age was identified by two-way 
ANOVA with Bonferroni correction, showing a significant reduc-
tion of DA levels in MI2 mice at 12 months compared to 12 month 
old C57Bl/6S mice, and to 3 month old and 6 month old MI2 mice 
(*p < 0.05, ***p < 0.001) (see also Supplementary Fig. S5a, Online 
Resource 1 and for DDPAC content S5c). b Striatal DA release was 
measured by in vivo microdialysis following the infusion of 50 mM 
KCl for 60  min between 40 and 100  min of the experiment. Data 
are expressed as a fold difference compared to the baseline fraction 
(0 min), normalized to the value obtained in age-matched C57Bl/6S 
controls at 60  min (mean ± SEM, n = 4–6 mice). At 3  months of 
age no difference between MI2 and C57Bl/6S mice was observed, 
but a significant progressive decrease in DA release was found at 6, 
9 and 12 months of age in MI2 compared with C57Bl/6S mice (see 
also Supplementary Fig. S5b, Online Resource 1). Two-way mixed 
ANOVA revealed a significant interaction between genotype and 
sample time at 6, 9 and 12 months of age (*p < 0.05, **p < 0.01, t test 
for individual sampling time points) (see detailed statistical evalua-
tion in Online Resource)
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significantly lower (by 43%) compared to that in 9 months-
old MI2 mice (Fig. 5b).
To confirm neuronal loss in SNpc and rule out the pos-
sibility that the decrease in TH cell number was reflecting 
a possible reduction in TH expression, cell counting was 
performed in 12 month-old mice following staining with 
the neuronal marker NeuN. NeuN and TH staining images 
were overlapped to delimit the counting area to the SNpc 
(Supplementary Fig. S6, Online Resource 1). The results 
showed a 20% reduction of NeuN positive neurons in 
SNpc of 12 month-old MI2 mice compared to C57Bl/6S 
[11,877 ± 383.5 (MI2) and 15,633.5 ± 1020.7 (C57Bl/6S) 
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cells; Fig. 5c]. The reason for the reduced proportional neu-
ronal loss observed following NeuN staining compared to 
TH staining is due to the fact that NeuN recognizes both 
TH and non-TH neurons in the SNpc, indeed, the absolute 
number of cell loss was similar for TH and NeuN stained 
neurons (− 3868 and − 3757 neurons, respectively).
We then assessed changes in DA innervation in the stria-
tum of MI2 mice at different ages. We observed a significant 
decrease in striatal  TH+ innervation at 12 but not at 9 months 
in MI2 mice compared to C57Bl/6S mice (Fig. 5d). In order 
to determine the loss of striatal innervation, we evaluated 
the density of TH-positive fibers by estimating their length 
in a defined volume of striatal tissue. We found that MI2 
mice had a 40% loss of striatal TH innervation compared to 
C57Bl/6S mice (14.49 ± 0.77 and 24.29 ± 1.76 nm per µm3, 
respectively) at 12 months of age while no significant differ-
ence was present in 9 month-old MI2 mice compared to con-
trols (21.88 ± 2.48 and 25.6 ± 3.31 nm per µm3, respectively; 
Fig. 5e). These results indicate that similar to the loss of nigral 
DA neurons, loss of nigrostriatal DA innervation occurs after 
the functional synaptic deficit, reflected by a reduction in DA 
stimulated release that starts at 6 months of age.
Motor impairment in MI2 mice
An accelerating rotarod test was initially used to analyze 
motor function in MI2 mice at 6, 12, 15 and 20 months 
of age. An age-related gradual decline in rotarod perfor-
mance was present in both C57Bl/6S and MI2 mice, but 
the reduction was more pronounced in MI2 mice, resulting 
in a significant loss of latency to fall from the rotarod at 
20 months of age compared to their performance at 6 and 
12 months of age (127.8 ± 14.9 s, 20 m, 215.8 ± 9.9 s, 12 m, 
220.7 ± 11.5 s, 6 m; Fig. 6a). The performance of MI2 mice 
at 20 months of age was also significantly impaired com-
pared to age-matched C57Bl/6S controls (127.8 ± 14.9 s and 
181.7 ± 21.6 s, respectively; Fig. 6a).
The presence of a motor deficit was also tested in 
20 month-old MI2 compared to C57Bl/6S mice using the 
static rod test where the time required to turn  180o from 
the initial position (orientation time) and the time required 
to travel from the far end of the rod to the platform (transit 
time) were measured. We found no significant differences 
between transgenic and control mice in either orientation 
or transit time when a 25 mm diameter rod was used, but 
when the test was performed with a 15 mm rod, although 
there was no significant difference in the orientation time, 
the transit time was longer for MI2 mice compared to con-
trols (12.8 ± 1.6 s and 8.1 ± 0.8 s, respectively), confirming 
a selective motor impairment in MI2 mice (Fig. 6b).
To determine whether earlier subtle changes were present 
in motor behavior, we tested MI2 male mice using the more 
sensitive DigiGait system. The animals were weighed prior to 
the experiments, and we identified a trend towards increased 
body weight in MI2 males that however reached the signif-
icance only at 18 months of age (Supplementary Fig. S7a, 
Online Resource 1). The results of the DigiGait assessment 
show alterations in the gait pattern of MI2 mice in compari-
son with C57Bl/6S animals starting from 9 months of age, 
and were manifested by decreased forelimb stride length 
(4.256 ± 0.178 cm vs. 4.756 ± 0.14 cm) and forelimb stance 
(0.303 ± 0.014 s vs. 0.334 ± 0.009 s), swing (0.123 ± 0.005 s 
vs. 0.141 ± 0.007  s) and propulsion (0.191 ± 0.009  s vs. 
0.219 ± 0.008 s) duration, that was still present at the end of the 
test at 18 months of age (Fig. 6c). Impairment of hindlimb gait 
pattern was less evident, however, a trend towards a decrease in 
MI2 mice was present at older ages for hindlimb stride length 
and hindlimb stance and swing duration (Supplementary Fig. 
S7b, Online Resource 1). Statistically significant differences 
were found between hindlimb of MI2 mice and C57Bl/6S 
animals in propulsion duration at 18 months (0.251 ± 0.01 s 
vs. 0.276 ± 0.005 s) (Fig. 6c), and in brake duration at 6 and 
18 months (Supplementary Fig. S7b, Online Resource 1).
The oligomer modulator, anle138b, rescues DA 
deficit in MI2 mice
MI2 mice reproduce key features of PD, progressive 
aggregation of αSyn in the nigrostriatal system, progres-
sive impairment of striatal DA release, reduction in total 
striatal DA, loss of nigrostriatal DA fibers and nigral DA 
neurons and motor impairment when the SNpc DA neuron 
loss reaches 50%. This MI2 mouse line, therefore, appears 
appropriate for testing potential therapies for PD. Hence, 
Fig. 5  Loss of dopaminergic neurons in SNpc of MI2 mice. a Immu-
nohistochemistry showed a reduction in TH staining in SNpc of MI2 
mice compared to C57Bl/6S animals at 12 and 20 months of age. b 
Stereological counting of TH-positive neurons in SNpc. Average 
number of nigral TH-positive cells ± SEM, n = 4–6 mice per group; 
two-way ANOVA with Bonferroni correction showing a significant 
reduction of  TH+ neurons in MI2 mice compared to C57Bl/6S con-
trols at 12 (*p < 0.05) and 20 (***p < 0.001) months of age. There 
was also a significant reduction in  TH+ cells in MI2 mice between 
9 and 20  months of age. c Stereological counting of total,  NeuN+ 
neuron number in SNpc at 12  months of age (see also Supplemen-
tary Fig. S6, Online Resource 1). A significant decrease of  NeuN+ 
neurons is present in MI2 mice compared to C57Bl/6S mice (average 
number of nigral NeuN-positive cells ± SEM, n = 4 mice per group; t 
test, *p < 0.05). d Reduced TH-positive fiber staining in the striatum 
of MI2 mice compared to C57Bl/6S mice at 12 months of age. Insets 
show high magnification images. e  TH+ striatal neurites were esti-
mated using the spaceball probe (mean length of striatal  TH+ fibers 
per volume of striatal tissue ± SEM, n = 4–6 mice per group; effect of 
genotype was identified by two-way ANOVA). Significant decrease 
in the total length of  TH+ fibers was present in 12  month-old MI2 
mice compared to 12 month-old C57Bl/6S mice (**p < 0.01) and 12 
and 9 month-old MI2 animals (*p < 0.05), multiple comparisons with 
Bonferroni corrections (see detailed statistical evaluation for 5b, 5c, 
5e in Online Resource)
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we investigated if a small molecule modulator of aggre-
gation, anle138b was able to rescue DA impairment in 
MI2 mice. Furthermore, we used dSTORM imaging and 
analysis to determine how anle138b acts in vivo and how 
it affects the spatial distribution of striatal 1–120 hαSyn.
Anle138b was administered in the food (2 g/kg of food) 
for 3 months to MI2 and C57Bl/6S mice. Treatment with 
Fig. 6  Motor impairment in MI2 mice. a C57Bl/6S and MI2 
mice were analyzed using accelerating rotarod test at 6, 12, 15 
and 20  months of age (mean latency to fall from the rod ± SEM, 
n = 12–18 mice per group). A main effect of age was identified by 
two-way ANOVA. Statistically significant differences between 6 
and 20  months (###p < 0.001) and 12 and 20  months (‡‡‡p < 0.001) 
in MI2 mice, and between MI2 and C57Bl/6S animals at 20 months 
(*p < 0.05) were revealed by multiple comparisons with Bonfer-
roni correction. b Motor performance of 20  month-old mice was 
tested using the static rod test (mean orientation time or mean tran-
sit time ± SEM, n = 13–18 mice). No differences were identified 
between experimental groups using a 25  mm rod or in orientation 
time using a 15 mm rod, but there was a statistically significant dif-
ference in transit time on the 15 mm rod between MI2 and C57Bl/6S 
mice (*p < 0.05, t test). c Gait pattern of mice was analyzed between 
3 and 18 months of age using DigiGait test (see also Supplementary 
Fig. S7, Online Resource 1). Alterations in individual gait phases 
were found in MI2 animals compared to control C57Bl/6S mice 
(mean ± SEM, n = 9–17 male mice per group). Two-way ANOVA 
identified a main effect of age on forelimb stance and swing duration, 
and on hindlimb propulsion duration, a main effect of genotype on 
forelimb stride length and stance, swing and propulsion duration, and 
two-way interaction between age and genotype for forelimb propul-
sion duration. Statistically significant differences were identified at 9, 
12 and 18  months for forelimb stride length and stance, swing and 
propulsion duration, and at 18 months for hindlimb propulsion dura-
tion (*p < 0.05; **p < 0.01, ***p < 0.001) by pairwise comparisons 
with Bonferroni correction between MI2 and C57Bl/6S mice (see 
detailed statistical evaluation in Online Resource)
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anle138b or placebo started at 9 months of age, when stri-
atal DA release impairment is already present in MI2 mice, 
and ended at 12 months of age when 30% nigral neuron 
loss is detected in non-treated animals (Fig. 7a). Using 
immunohistochemistry, we found that anle138b treatment 
reduced 1–120 hαSyn aggregation in both SNpc cell bodies 
and synaptic terminals in the striatum (Fig. 7b). Applica-
tion of dSTORM analysis not only confirmed the reduc-
tion in striatal 1–120 hαSyn aggregation but also provided 
a mechanistic explanation for anle138b activity. dSTORM 
analysis revealed two opposite but complementary effects 
of anle138b: we detected an increased percentage of small, 
non-clustered 1–120 hαSyn species (anle138b, 53.4 ± 2.9%; 
placebo, 29.9 ± 3%; Fig. 7c, d) that occurred concomitantly 
with a reduction in the inner density of small and large size 
aggregates (anle138b, 140.9 ± 12.7; placebo, 233.5 ± 25.3 
fluorophore localizations; Fig. 7c, d). The total number of 
aggregates was only slightly but not significantly reduced 
following anle138b treatment (Fig. 7d). Analyses of striatal 
extracts by immunoblotting confirmed this result showing 
a reduction in HMW 1–120 hαSyn band and an increase in 
monomeric protein (Fig. 7e). These data show that anle138b 
substantially affects the aggregation profile of 1–120 hαSyn 
in MI2 mice.
Accordingly, we speculated that the non-aggregated small 
1–120 hαSyn species, revealed by dSTORM, whose num-
ber increased following anle138b treatment may represent 
monomers or small 1–120 hαSyn assemblies. To examine 
this hypothesis, we compared the size distribution of the 
non-aggregated population in MI2 mouse striatum to the 
size distribution of recombinant monomeric hαSyn. Recom-
binant hαSyn was plated at low density onto a coverslip, 
immunolabeled, and imaged using the same protocol as that 
used to visualize 1–120 hαSyn in MI2 striatal slices. Map-
ping the recombinant hαSyn population resulted in a size 
distribution with a mean diameter of 23 nm and an average 
of 7 localizations per protein (Supplementary Fig. S8a, b, 
Online Resource 1). Using the same parameters of cluster-
ing, we observed that following anle138b treatment, 85% of 
1–120 hαSyn population in MI2 mouse striatum had a very 
similar size distribution with a mean diameter of 23 nm and 
an average of 7 localizations per protein (Supplementary 
Fig. S8c, d, Online Resource 1). These data suggest that 
anle138b treatment resulted in an increase most probably 
of monomeric and small assemblies of monomeric hαSyn 
species that could have been possibly either released from 
dissolving aggregates or not recruited to them.
To determine the effect of anle138b on dopaminergic 
impairment, we measured striatal DA release in MI2 mice. A 
3-month treatment was started at the age of 9 months when the 
DA release deficit was already present. Released DA was sig-
nificantly increased in anle138b-treated MI2 mice compared 
to placebo-treated MI2 animals [Fig. 8a;  K+-stimulated DA 
release, relative values of DA release in anle138b- vs placebo-
treated MI2 mice sampled at 60, 80 and 100 min, after nor-
malized to peak C57Bl/6S mouse fraction value (at 60 min) 
reached 0.69 ± 0.14 vs 0.13 ± 0.02 (60 min), 0.36 ± 0.07 
vs 0.07 ± 0.01 (80  min) and 0.28 ± 0.05 vs 0.09 ± 0.02 
(100 min)]. The DA release values in C57Bl/6S anle138b- 
vs placebo treated mice were not altered [1.03 ± 0.25 vs 
1 ± 0.12 (60 min), 0.41 ± 0.09 vs 0.55 ± 0.05 (80 min) and 
0.38 ± 0.09 vs 0.39 ± 0.03 (100 min) (Fig. 8a)]. We then 
analyzed the effect of anle138b treatment on the number of 
nigral DA neurons and found a significant increase in number 
of  TH+ neurons in SNpc of anle138b-treated MI2 animals 
compared to placebo-treated mice (Fig. 8b), with anle138b 
preventing cell loss. The number of nigral  TH+ cells did not 
differ between C57Bl/6S mice treated with either placebo or 
anle138b (10,886.7 ± 706.5 and 10,792 ± 858.9  TH+ cells, 
respectively) and anle138b-treated MI2 mice (9944 ± 567.5 
 TH+ cells), while a substantial DA neuron loss was present in 
placebo-treated MI2 mice (7465 ± 41.4  TH+ cells) (Fig. 8c).
To determine whether anle138b treatment can affect 
motor dysfunction, we tested the mice before, during and 
at the end of treatment using DigiGait system. Mice were 
weighed before each test, and we found no effect of treat-
ment on the body weight, what shows that body weight 
differences didn’t contribute to behavioral differences 
between anle138b- and placebo-treated animals over the 
course of the experiment. An effect of genotype on the 
body weight was identified only at 12 months of age when 
MI2 mice were heavier than controls (Supplementary Fig. 
S9a, Online Resource 1). We found that anle138b rescued 
several of the parameters associated with the motor impair-
ment (Fig. 9; Supplementary Fig. S9b, Online Resource 
1). We observed that MI2 mice treated with anle138b, in 
comparison with MI2 mice treated with placebo, exhib-
ited increased forelimb stride length (4.417 ± 0.094 cm 
vs. 4.025 ± 0.131  cm, respectively) and stance dura-
tion (0.302 ± 0.006 s vs. 0.279 ± 0.008 s, respectively) at 
12 months of age, hindlimb stance duration at 10.5 months 
of age (0.31 ± 0.009 s vs. 0.275 ± 0.015 s, respectively), as 
well as forelimb (0.201 ± 0.01 s vs. 0.168 ± 0.0125 s, respec-
tively) and hindlimb (0.262 ± 0.009 s vs. 0.226 ± 0.016 s, 
respectively) propulsion duration at 10.5 months of age 
(Fig. 9). When we compared placebo-treated MI2 mice 
with placebo-treated C57Bl/6S mice, the length of fore-
limb stride at 10.5 (4.092 ± 0.22 cm vs. 4.659 ± 0.156 cm, 
respectively) and 12 (4.025 ± 0.131 cm vs. 4.576 ± 0.136 cm, 
respectively) months of age and hindlimb stride at 10.5 
(3.808 ± 0.211  cm vs. 4.345 ± 0.108  cm, respectively), 
and 12 (3.929 ± 0.133 cm vs. 4.429 ± 0.151 cm, respec-
tively) months of age as well as duration of forelimb stance 
at 10.5 (0.281 ± 0.015 s vs. 0.321 ± 0.01 s, respectively) 
and 12 (0.28 ± 0.009 s vs. 0.309 ± 0.009 s, respectively) 
months of age, hindlimb stance at 10.5 (0.275 ± 0.015 s vs. 
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0.326 ± 0.008 s, respectively) and 12 (0.287 ± 0.009 s vs. 
0.331 ± 0.011 s, respectively) months of age, forelimb pro-
pulsion at 10.5 months (0.168 ± 0.012 s vs. 0.204 ± 0.009 s, 
respectively) of age and hindlimb propulsion at 10.5 
(0.226 ± 0.016 s vs. 0.277 ± 0.009 s, respectively) and 12 
(0.234 ± 0.009 s vs. 0.29 ± 0.011 s, respectively) months of 
age was still decreased. However, we also observed statisti-
cally significant differences between anle138b-treated MI2 
mice and anle138b-treated C57Bl/6S mice in hindlimb stride 
length (4.144 ± 0.062 cm vs. 4.578 ± 0.169 cm, respectively) 
and stance duration (0.313 ± 0.006 s vs. 0.341 ± 0.012 s, 
respectively) at 12 months of age (Fig. 9). Taken together, 
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these results show that targeting αSyn aggregation by 
anle138b rescues the DA release deficit, several aspects of 
the gait impairment and protects against cell loss, even when 
treatment was started when synaptic functional impairment 
was already present.
Discussion
In PD, αSyn aggregation is associated with a reduction of 
total striatal DA, a decrease in striatal DA release and nerve 
cell loss in the SNpc which, when reaching around 50%, 
leads to overt motor impairment [5, 18]. Animal models 
recapitulating the progressing nature of αSyn pathology and 
DA dysfunction in PD are essential for testing new therapies. 
Here, we describe the MI2 mice, a new transgenic mouse 
model that expresses 1–120 hαSyn and shows a high similar-
ity to PD pathological features with progressive loss of DA 
and a deficit in striatal DA release, αSyn aggregation in SNpc 
neurons and their striatal terminals, dopaminergic neuronal 
death in the SNpc, as well as motor deficits as initial fine 
alterations in gait pattern, followed by significant impairment 
in motor function as detected by rotarod test when cell death 
reaches around 50%, similar to the human condition.
Previously we described another mouse line (α-Syn120 
mice) expressing the same α-Syn 1–120 transgene under 
the same TH promoter, that also showed progressive αSyn 
aggregation, SNARE protein redistribution and striatal DA 
dysfunction, however differently from the MI2 model these 
mice did not show DA neuron death in the SNpc and reduc-
tion of total DA in striatum occurred already at 3 months 
of age and was not progressive but remained constant [12, 
35], when, in the MI2 mice reduction of total striatal DA 
occurred instead at 12 months of age. In another model 
expressing 1–119 αSyn in TH neurons DA neuronal death 
was not found [8]. Why our two αSyn1–120 transgenic 
mouse lines differ is not clear but it could depend on the 
transgene insertion site in the mouse genome (chromosome 
10 in MI2 and chromosome 3 in α-Syn120 mice) or be 
related to the expression level of the transgene that although 
expressed under the same promoter appears lower in the 
MI2 mice compared to the α-Syn120 line. Further studies 
are needed to clarify the reasons for the differences between 
our two 1–120 αSyn transgenic lines.
Dopaminergic pathology in MI2 mice was associated with 
changes in 1–120 hαSyn protein distribution in SNpc and 
striatum accompanied by redistribution of SNARE proteins 
such as VAMP 2 (Supplementary Fig. S1, Online Resource 
1) similar to what we have previously described in transgenic 
α-Syn120 mice and PD brains [12] and was also reported 
in DLB cases [19]. In SNpc of MI2 mice 1–120 hαSyn 
appeared in neuronal cell bodies as multiple small inclusions 
at 1.5 months of age, while large LB-like structures were 
present in numerous cells by 12 months of age. Some of these 
α-Syn deposits were resistant to PK digestion and a small 
number of cells with α-Syn aggregates contained also ubiq-
uitin. Neuronal processes in the SNpc contained large dotted 
inclusions at 1.5 months of age, while in older mice processes 
were filled with dense aggregates, some of which exhibited 
PK resistance. This pattern indicates a progression in αSyn 
aggregation from small to large, less soluble structures, sim-
ilar to human α-synucleinopathies [21]. In the striatum of 
1.5 month-old MI2 mice, 1–120 hαSyn deposits were small, 
but widely distributed in the neuropil, and in older animals 
they were more frequent and of larger size. Both, in SNpc 
and striatum, the αSyn aggregates became more insoluble 
with time, as shown by the appearance of stable HMW bands 
in immunoblots of MI2 mouse brain extracts, and increased 
amounts of αSyn in detergent-insoluble fractions in sequen-
tial extraction experiments. PK treatment appeared to fully 
digest the striatal αSyn aggregates while this was not the case 
for the aggregates present in the SNpc. However, it cannot be 
excluded that in the striatum some αSyn aggregates survive 
the PK treatment but could be too small to be detected by 
conventional microscopy.
To further characterize the progression of striatal synaptic 
1–120 hαSyn aggregation, we used dSTORM, which allows 
detection of protein distribution at single molecule level and 
20 nm resolution. Although dSTORM has been successfully 
employed to study synaptic proteins [2–4, 11, 34] we believe 
that this is the first time that dSTORM is used to analyze 
Fig. 7  Effect of anle138b on αSyn aggregation in MI2 mice. a Mice 
were treated with anle138b starting at 9  months and analyzed at 
12 months of age. b Treatment with anle138b reduces the accumula-
tion of 1–120 hαSyn in SNpc and striatum of MI2 mice as shown by 
Syn1 antibody immunostaining. c Representative dSTORM images 
of 1–120 hαSyn staining in the striatum of 12 month old MI2 mice 
treated with placebo (top panel) or anle138b (bottom panel). Large 
aggregates appear less dense and an increased number of smaller 
species are seen following anle138b treatment. d Quantification of 
dSTORM data revealed a significant decrease in the inner density of 
aggregates (#localizations/cluster) and a significant increase in the 
percentage of non-clustered 1–120  hαSyn in anle138b-treated MI2 
mice compared to placebo-treated littermates (see also Supplemen-
tary Fig. S8, Online Resource 1) (mean ± SEM, n = 3 mice; t test, 
*p < 0.05, **p < 0.01) while the number of clusters and their size did 
not change significantly. e Immunoblotting of striatal brain extracts 
from 12  month-old mice shows a decrease of αSyn high molecular 
weight (HMW) bands (arrowhead) and an increase of monomeric 
αSyn (arrow) in the striatum of anle138b-treated MI2 mice compared 
to MI2 placebo treated. 1–120 hαSyn levels are also shown for 1.5, 9 
and 12 month-old untreated MI2 mice. C57Bl/6S (C57S) not express-
ing endogenous αSyn are shown as negative control. The star denotes 
non-specific bands recognized by Syn1 antibody. Blot shows levels of 
αSyn before and after anle138b in 3 mice representative of 5–6 mice 
per group tested. Right panel—quantification of HMW 1–120 hαSyn 
and monomeric (mono) 1–120 hαSyn after normalization to the lev-
els of β-actin in all 5–6 mice tested (fold difference compared to pla-
cebo-treated mice ± SEM, n = 5–6 mice per group, t test: **p < 0.01)
◂
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the progression and rescue of presynaptic αSyn pathology 
in vivo in brains of a PD mouse model. dSTORM confirmed 
a progressive aggregation of 1–120 hαSyn in the MI2 mouse 
striatum. Of all the parameters analyzed, cluster abundance 
and density (number of clusters per 20 µm2) of 1–120 hαSyn 
aggregates appeared to be the factors best associated with 
the reduction in striatal DA release. The presence of αSyn 
aggregates has been recently demonstrated by some of us 
using a different super resolution microscopy method (DNA 
PAINT) in induced pluripotent stem cells (iPSCs) from a 
patient with a triplication of the SNCA gene [38], however, 
one of the unique findings of the present study is the differ-
ential age-dependent effect on aggregate size. We found that 
only 20-500 nm aggregates were increased with age rather 
than aggregates larger than 500 nm. Thus, as the small αSyn 
species (< 250 nm) cannot be observed using conventional 
microscopy, establishing  dSTORM as a novel approach for 
the analysis of αSyn aggregation in vivo in mouse models.
Striatal impairment of DA release was observed in MI2 
animals before the measurable loss of DA cells in SNpc and 
DA innervation in the striatum (6 vs 12 months). This is con-
sistent with our previously reported α-Syn120 mice, where 
a deficit in striatal DA release was present in the absence 
of DA neuron death in SNpc [12]. This observation sup-
ports the hypothesis that synapses play a central role in PD 
pathogenesis, being the primary site of dysfunction before 
loss of neurites and neurons occur, supporting the notion of 
retrograde degeneration [6, 10].
Fig. 8  Effect of anle138b on striatal DA release and SNpc DA neu-
ron death in MI2 mice. a The effect of anle138b treatment on stri-
atal DA release studied by in  vivo microdialysis. Data are nor-
malized to the value obtained in the C57Bl/6S/placebo group at 
60  min (mean ± SEM, n = 5–6 mice per group). Three-way mixed 
ANOVA identified an effect of genotype, sampling time, two-way 
genotype × sampling time interaction, and sampling time × geno-
type × treatment three-way interaction. Statistically significant dif-
ferences in  K+-induced DA release at 60, 80 and 100  min were 
found between placebo-treated MI2 and C57Bl/6S mice (**p < 0.01, 
***p < 0.001) and between placebo- and anle138b-treated MI2 mice 
(#p < 0.01) (multiple comparisons with Bonferroni correction). b 
Preservation of TH immunoreactivity in SNpc of anle138b-treated 
MI2 mice compared with placebo-treated littermates. c Effect of 
anle138b treatment on nigral DA neuronal death determined using 
stereology (average number of nigral TH-positive cells ± SEM, n = 3 
mice per group). A main effect of genotype was identified by two-way 
ANOVA. Anle138b treatment resulted in increased number of  TH+ 
cells in MI2 mice compared to placebo-treated littermates (*p < 0.05). 
Placebo-treated MI2 mice had less nigral  TH+ cells than placebo-
treated C57Bl/6S mice (*p < 0.05, multiple comparisons with Bon-
ferroni correction) (see detailed statistical evaluation in Online 
Resource)
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Overt motor phenotype occurred in MI2 mice when 
around 50% of SNpc DA neurons were lost similar to human 
PD [5, 18], however subtle changes in gait pattern were 
found earlier. We observed decrease in the propulsion dura-
tion, resulting in reduced duration of stance, that, together 
with shorter swing phase, lead to decreased length of the 
stride. This phenotype can be compared with the walking 
alterations characteristic for PD patients, where shorter 
stride length is often observed and is believed to be related 
with slow, shuffling gait characteristic for the disease [22, 
25]. Decrease in stride has also been reported before in other 
models of PD, including transgenic A53T mice [27], and 
pharmacological MPTP model [14]. We then used MI2 mice 
to test whether DA pathology might be rescued by target-
ing neuronal αSyn aggregation with anle138b, which has 
previously been shown to have beneficial effects by interact-
ing specifically with structural epitopes of various protein 
aggregates and to rescue protein aggregation and related 
pathological features in models with αSyn, prion and tau 
aggregation [23, 36, 37]. Unlike the MI2 mice, the αSyn 
transgenic models used in previous anle138b studies did not 
present with consistent neuronal nigrostriatal αSyn aggrega-
tion or αSyn-related progressive dopaminergic impairment 
with motor impairment related in some cases more to spinal 
cord pathology [37] or αSyn pathology in oligodendrocytes 
[15]. Thus, our study is the first to investigate the effects of 
anle138b in a model with nigrostriatal neuronal DA altera-
tions and neuronal αSyn aggregation as observed in PD. 
We show that a 3 month-treatment with anle138b (started 
at 9 months of age, when a deficit in striatal DA release 
but no significant neuronal loss is present) rescues DA dys-
function, prevents nerve cell death, and, to a large degree, 
protects from gait deficits. The reason why not all gait abnor-
malities are rescued by anle138b treatment remains to be 
investigated.
The results of our study are of particular significance 
because they show the presence of a time window, when DA 
function can still be rescued and neuronal death prevented 
despite the presence of αSyn-related synaptic alterations and 
subtle behavioral changes. Anle138b significantly changed 
1–120 hαSyn aggregation in the striatum and SNpc of MI2 
mice, as observed by immunohistochemistry and immuno-
blotting. However, more information on its mechanism of 
action in vivo was obtained by dSTORM, which showed 
an increase in the percentage of small, non-clustered αSyn 
species in the striatum following anle138b administration. 
These species are likely to represent monomers and small 
assemblies of monomeric αSyn as determined by compar-
ing their size to the size of recombinant hαSyn spread on 
a coverslip and immunostained as in the brain tissue and 
similarly examined with dSTORM. This analysis was an 
approximation since it compared the transgenic truncated 
1–120 protein with full-length recombinant hαSyn but this 
Fig. 9  Effect of anle138b on gait pattern in MI2 mice (see also Sup-
plementary Fig. S9, Online Resource 1). Placebo- or anle138b-treated 
C57Bl/6S and MI2 mice were analyzed using the DigiGait test. Treatment 
with anle138b rescued alterations in the duration of several of gait phases 
in MI2 mice (mean ± SEM, n = 6–12 mice per group; males and females). 
Three-way ANOVA revealed a main effect of age and a main effect of 
genotype on forelimb and hindlimb stride length, and stance and propul-
sion duration, a main effect of treatment on hindlimb stance and propul-
sion duration and a three-way age × genotype × treatment interaction for 
forelimb stance duration. At 10.5  months of age, statistically significant 
differences were found between placebo-treated C57Bl/6S and MI2 mice 
in forelimb and hindlimb stride length, and in forelimb and hindlimb 
stance and propulsion duration (#p < 0.05, ##p < 0.01), and between pla-
cebo- and anle138b-treated MI2 mice in hindlimb stance duration and in 
forelimb and hindlimb propulsion duration (*p < 0.05). At 12 months of 
age, statistically significant differences were identified between placebo-
treated C57Bl/6S and MI2 mice in forelimb and hindlimb stride length 
and stance duration, and in hindlimb propulsion duration (#p < 0.05, 
##p < 0.01). At this age, a difference was found between anle138b-treated 
C57Bl/6S and MI2 mice in hindlimb stride length and stance duration 
(‡p < 0.05) and between placebo- and anle138b-treated MI2 mice in fore-
limb stride length and stance duration (*p < 0.05) (multiple comparisons 
with Bonferroni correction) (see detailed statistical evaluation in Online 
Resource)
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was done because the recombinant truncated protein has a 
greatly increased tendency to aggregate [7] making it dif-
ficult to determine the presence of bona fide monomeric 
species.
Moreover, after anle138b treatment, dense aggregates 
showed a significant reduction in inner density. This sug-
gests that anle138b in vivo could interfere with aggregation 
by preventing the formation of new aggregates and/or the 
recruitment of non-aggregated 1–120 hαSyn into existing 
aggregates possibly destabilizing them, thus leading to a 
reduction of their inner density, resulting in both cases in an 
increase in small, non-clustered αSyn species in the environ-
ment. Whether the anle138b effect is related to one or both 
of these mechanisms could be only established by monitor-
ing aggregation of hαSyn with dSTORM in anle138b-treated 
MI2 mice over time.
It remains to be clarified, how anle138b produced its ben-
eficial effect, whether the effect is related to the reduced 
toxicity of less dense aggregates or to the increase in small 
αSyn species, which could be physiologically active and 
restore DA release. It will be interesting to see if removal 
of small αSyn species by inducing their degradation can 
potentiate the effects of anle138b by further reducing pos-
sible aggregation or reduce its effect, as it could be expected 
if the small αSyn species are functional.
In summary, we report here a transgenic mouse model 
that recapitulates the progressive αSyn aggregation and 
DA neuron dysfunction and death observed in human PD. 
Striatal synaptic DA dysfunction preceded SNpc DA neu-
ronal death and loss of striatal TH terminals, supporting 
synaptic dysfunction as being an early pathogenic factor in 
PD. Anle138b restored DA function, rescued several gait 
abnormalities and prevented nerve cell loss by disrupting 
αSyn aggregate formation as shown for the first time by 
using dSTORM. Overall, this study indicates that MI2 mice 
are a suitable model to test mechanism-based therapies for 
α-synucleinopathies, and dSTORM is a useful technique for 
studying structural/morphological changes related to aggre-
gate toxicity. This work also indicates that there is a window 
of time when it is possible to prevent DA neuronal death, 
even when striatal DA release is already impaired.
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